Key result
Higher lipophilicity of oral triptans did not significantly correlate with improved efficacy, but showed some correlation with higher central nervous system adverse events (r=0.74, P=0.09).
Why the study?
Does higher lipophilicity of oral triptans improve efficacy or tolerability in migraine patients?
Does higher lipophilicity of oral triptans improve efficacy or tolerability in migraine patients?
Higher lipophilicity of oral triptans does not significantly improve efficacy but may correlate with higher central nervous system adverse events and lower recurrence rates.
Answers are grounded in this paper and cite their sources.
Higher lipophilicity offers no efficacy gain with oral triptans; challenges CNS-penetration assumptions and flags potential adverse-event trade-offs.
BACKGROUND: It has been suggested that triptans achieving higher central nervous system (CNS) levels should have an advantage in efficacy, if central actions are important. Objective.-Our aim was to correlate the efficacy and tolerability results of triptans with their lipophilicity. METHODS: Data for response and pain free at 2 hours, recurrence, adverse events (AE), CNS AE, and chest symptoms taken from Ferrari et al's meta-analysis publications for the recommended doses of oral triptans were correlated with their lipophilicity coefficients (logD(pH)7.4 = -2.1 almotriptan < -1.5 sumatriptan < -1.0 zolmitriptan < -0.7 rizatriptan < -0.2 naratriptan < 0.5 eletriptan). RESULTS: We found no significant correlation between lipophilicity coefficients and any of the analyzed parameters. There was, however, some correlation between lipophilicity and CNS AE (P = .09, r = 0.74) and, to a lesser degree, with a reduction in recurrence rate (r = -0.36). The r values for response and pain free with placebo correction ranged from 0.04 to 0.34, suggesting almost no correlation between lipophilicity and efficacy variables. CONCLUSIONS: According to this analysis, a higher lipophilicity does not seem crucial to improve triptan efficacy. This physico-chemical property, however, correlates with higher CNS AE and, possibly, lower recurrence rates.
No takes yet. Share an insight, caveat, or question.
Pascual et al. (2004) studied this question. Lipophilicity of oral triptans was evaluated on Efficacy and tolerability (response and pain free at 2 hours, recurrence, AE, CNS AE, chest symptoms) (r = 0.74, p=.09). Higher lipophilicity of oral triptans did not significantly correlate with improved efficacy, but showed some correlation with higher central nervous system adverse events (r=0.74, P=0.09).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: